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able effects. The impact of adopting a longer time horizon to capture very late stent 
thrombosis needs to be examined. The model developed in this study will be used to 
facilitate further development of the biomarker test.
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OBJECTIVES: To assess the cost utility analysis of lifestyle interventions (diet, physi-
cal activity and diet + physical activity) at primary care for person with high risk of 
cardiovascular disease by using a Markov model. METHODS: A cost-utility analysis 
was performed using a 10-state Markov model of CVD (cardiovascular disease) events 
applied to a cohort of 60 year-old men from the county of Stockholm, Sweden. a 
previously performed randomized controlled trial of dietary advice, physical exercise 
and diet + physical exercise on middle aged men of Sweden (The Sollentuna study) 
was used as effectiveness of intervention. The risk of having a CVD event in primary 
care was taken from The Framingham Heart Study. Lifetime costs and health effects 
(QALYs, quality-adjusted life-years) were estimated, in both a health care and societal 
perspective with 3% discount rate. RESULTS: The model predicts physical exercise 
to be the best option at zero willingness to pay and dietary advice the best if the 
decision-maker willingness to pay is higher than 60,000 SEK per QALY (1 Euro = 
10.74 SEK (2009). The incremental cost-effectiveness ratio (ICER), compared with no 
intervention is 77,000 SEK/ QALY from a health care perspective and 57,000 SEK/
QALY from a societal perspective. CONCLUSIONS: Based on the model estimates, 
dietary advice and physical exercise both are cost-effective interventions, and the 
choice depends upon the decision-maker willingness to pay.
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OBJECTIVES: To estimate the expected value of perfect information (EVPI) associ-
ated with a lifetime Markov-model which evaluated the cost-effectiveness of rivaroxa-
ban and dabigatran compared to enoxaparin for venous thromboembolism (VTE) 
prophylaxis after total hip replacement (THR). To estimate the expected value of 
perfect parameter information (EVPPI). To indentify the model parameter subset 
whose uncertainty drives the decision uncertainty. To decrease the uncertainty, by 
collecting additional data on this subset. To investigate the impact of threshold change 
on the EVPI/EVPPI values. METHODS: EVPI was determined directly from PSA and 
was calculated over the threshold c0–100,000/QALY. Population EVPI (PEVPI) was 
calculated based on the 5464 THR procedures performed in Ireland in 2006 and the 
ENDORSE-study which revealed that 64% of at risk surgical patients in Ireland 
receive recommended VTE prophylaxis. The assumptions were; a 50% policy of 
choice uptake rate, a 4% discount rate and a 10-year time horizon. Alternative 
assumptions of 5 and 15 years were explored. EVPPI were calculated for the 3 param-
eter subsets using the 2-stage Monte-Carlo algorithm. RESULTS: Base-case analysis 
indicated that rivaroxaban dominated. Probabilistic analysis (PSA) indicated that at 
c45,000/QALY, the probability that rivaroxaban was the most cost-effective strategy 
was 67%. The PEVPI was c15.62 million. Costs had the highest EVPPI (c12.43 
million), followed by probabilities (c1.45 million) and preference weights (c1.44 
million). The costs subset was most sensitive to threshold. Costs were updated with 
a more detailed costing study. All analyses were repeated. Base-case analysis indicated 
that rivaroxaban continued to dominate. The probability that rivaroxaban was the 
most cost-effective strategy increased to 81%. PEVPI decreased to c4.59 million. 
EVPPI for costs decreased to c2.13 million. EVPPI for probabilities and preference 
weights were c1.03 million and c0.94 million respectively. CONCLUSIONS: This 
study demonstrates the application of EVPI/EVPPI analyses to quantify and decrease 
uncertainty associated with the choice of VTE prophylaxis after THR in the Irish 
health care setting. 
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OBJECTIVES: To compare patient persistence with chronic-use prescription medica-
tions between once- (QD) and twice-daily (BID) dosing. METHODS: Using a large 
claims database (MarketScan), prescription medications were deﬁ ned as QD if ≥80% 
of claims showed a quantity/day = 1 and as BID if ≥80% of claims had a quantity/
day = 2. Data for patients (18 years or older) with a ﬁ rst claim in 2007 were selected 
for analysis and were further limited to 4 classes of medications frequently used by 
cardiovascular patients: antiplatelet, general cardiac, antihyperlipidemic, or antidia-
betic medications. Persistence was measured by time-to-discontinuation (TTD), 
deﬁ ned as the number of days from the ﬁ rst prescription ﬁ lled to the ﬁ rst gap of >30 
days between exhausting the supplied medication and ﬁ lling the next prescription. The 
mean TTD with censoring at 365 days was estimated. a proportional hazards model 
accounting for within-patient correlations in patients using multiple medications was 
used to model the TTD. The model was stratiﬁ ed on medication class and adjusted 
for baseline confounding variables (gender, age, Charlson Comorbidity Index). 
RESULTS: A total of 1,077,936 patients were included, and the number of patient-
medication combinations was 1,440,917 (QD: 1,384,565 and BID: 56,352). The 
estimated mean TTD for BID compared to QD was −8% overall (P < 0.01) and −32% 
for antiplatelet agents (P < 0.01), −22% for antihyperlipidemic agents (P < 0.01), 
−10% for antidiabetic agents (P < 0.01), and 1% for cardiac agents (P < 0.05). 
CONCLUSIONS: In this unique, recent, claims analysis, investigating multiple thera-
peutic classes of medications in a large database, persistence with antidiabetic, anti-
hyperlipidemic, and antiplatelet agents was greater with QD compared with BID 
dosing; however, a wide range in the differences in persistence between QD and BID 
dosing was noted between therapeutic classes. Persistence may prevent subsequent 
adverse events.
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OBJECTIVES: Various studies have sought to determine the impact of medication 
adherence on medical expenditure among the elderly with chronic conditions. To date, 
none have looked explicitly at adherence to treatment in cardiac failure, a common 
condition in the elderly. This study had two aims: 1) to measure adherence to treat-
ment for recommended heart failure medications, and 2) to assess whether better 
adherence is associated with lower spending among Medicare beneﬁ ciaries. 
METHODS: We used data from the 1997–2005 Medicare Current Beneﬁ ciary Survey 
to track utilization rates for cardiac failure medications over three years in a nation-
ally-representative sample of Medicare beneﬁ ciaries. The relationship between MPR 
and Medicare costs was tested in a sequence of multivariate models with extensive 
behavioral variables to control for healthy adherer bias and reverse causality. 
RESULTS: Over 3 years, median MPR values were 0.77 for ACE-I/ARB users, 0.74 
for beta blockers, 0.82 for diuretics and 0.74 for cardiac glycosides. Higher adherence 
rates were consistently associated with lower Medicare spending in every model tested. 
The estimated marginal effect of a 10 point increase in MPR for an ACE-I or ARB 
was a reduction in cumulative 3-year Medicare spending of $390 (P < 0.05) in 2006 
dollars. Similar increases in MPRs for beta blocker, diuretics, and cardiac glycosides 
were associated with $861 (P < 0.01), $520 (P < 0.01) and $2318 (P < 0.01) in lower 
Medicare costs respectively over three years. CONCLUSIONS: Higher levels of adher-
ence to recommended CHF regimens by Medicare beneﬁ ciaries were associated with 
lower cumulative Medicare spending over three years, with savings generally exceed-
ing the cost of the drugs.
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OBJECTIVES: Inaccurate use of chronic medication is associated with worse disease 
prognosis and high health care costs. Differences in drug prices might be outweighted 
by differences in costs due to compliance and persistence. The aim of this study was 
to investigate compliance and persistence with antihypertensive agents acting on the 
renin-angiotensin-aldosterone-system (RAAS). METHODS: A cohort study was con-
ducted based on pharmacy dispensing records (IADB.nl). Subjects were included who 
initiated treatment with either ACE-inhibitors (ACEi) or angiotensin receptor blockers 
(ARBs) between 1999 and 2007. a standardized toolbox was used, Reﬁ ll-Sequence 
analyses (RS) measured persistence; Proportion of Days Covered analyses (PDC) 
measured one-year compliance. Differences in persistence were adjusted for age, 
gender and time of treatment initiation. RESULTS: A total of 27,544 patients initiated 
treatment with ACEi; 8,649 patients initiated treatment with ARBs. Using a grace 
period of 60 days, persistence with ARBs was better compared to ACEi, adjusted HR: 
0.90 (95%CI: 0.84–0.96). Using a PDC cutpoint of 80%, one-year compliance with 
ARBa was also better compared to ACEi, 83.9% vs. 86.3%, P < 0.01. Within ACEi’s, 
differences in persistence between drugs were small. Within ARBs, persistence with 
losartan or valsertan was higher compared to irbesartan or candesartan, adjusted HR: 
0.82 (0.74–0.90). Compliance within ARBs however was similar for all drugs (P = 
0.27). Results were consistent when other grace periods or PDC cutpoints were used. 
CONCLUSIONS: Chronic users of ARBs were more compliant and persistent com-
pared to users of ACEi. Differences in persistence within ARBs might be due to dif-
ferences in drug tolerability and safety, but also due to differences in drug indications. 
Further results will be presented further exploring these ﬁ ndings, as well as analyzing 
differences in persistence between branded versus generic ACEi.
